

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSENER OF PATENTS AND TRADEMARKS
USASINGTON DC 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09.543,782	04/06/2000	D. Zucker-Franklin	ZUCKER-FRANKLIN-1A	8307
1444	7590 09 13 2002			
BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW SUITE 300 WASHINGTON, DC 20001-5303			EXAMINER	
			STRZELECKA, TERESA E	
			ART UNIT	PAPER NUMBER
			1637	<u> </u>
			DATE MAILED: 09/13/2002	15

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/543,782	ZUCKER-FRANKLIN ET AL.			
		Examiner	Art Unit			
		Teresa E Strzelecka	1637			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1)[	Responsive to communication(s) filed on 05 J	luly 2002 .				
2a) <u></u> ⊾	This action is <b>FINAL</b> . 2b) Th	is action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
	4) Claim(s) 11-13 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
· <u> </u>	Claim(s) is/are allowed.					
	i)[·] Claim(s) <u>11 and 13</u> is/are rejected.					
	Claim(s) <u>12</u> is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.  Application Papers						
	The specification is objected to by the Examine					
10) 🗌 🗀	The drawing(s) filed on is/are: a)□ accep	oted or b) objected to by the	e Examiner.			
	Applicant may not request that any objection to the	•	` <b>'</b>			
11) 🔲 -	The proposed drawing correction filed on		approved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Info	mmary (PTO-413) Paper No(s) ormal Patent Application (PTO-152)			
S Patent and Tr	ademark Office					

Application/Control Number: 09/543,782 Page 2

Art Unit: 1637

#### **DETAILED ACTION**

1. This Office action is in response to an amendment filed on July 5, 2002.

## Response to Arguments

- 2. In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., the potential blood donors not being tested for antibodies to at least one of HTLV-I or HTLV-II) are not recited in the rejected claims 11 and 13, only in claim 12. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Therefore Claims 11 and 13 remain rejected over Zucker-Franklin et al.
- Applicants did not address the rejection of claim 11 under 35 U.S.C. 112, second paragraph. Claim 11 was rejected as being indefinite because the test positive for the presence of HTLV-I or HTLV-II tax protein does not indicate the presence of the tax protein or antibodies to it. The method claim 11 would require active method step(s) (testing for the tax protein or antibodies to it), especially since the last step, d, contains a limitation "... if the test for at least one of (a), (b) or (c) is positive...". It is also unclear why step (b) is necessary after determining the presence of the DNA encoding the tax protein in the previous step. This rejection is maintained.

## Claim Objections

4. Claim 11 is objected to because of the following informalities: "... a potential donors...".

Appropriate correction is required.

## Claim Rejections - 35 USC § 112

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 09/543,782

Art Unit: 1637

6. Claims 11-13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 11 is drawn to a method for screening blood donors, the method comprising the steps of (i) testing a sample from the donors for the presence of DNA which encodes the HTLV-I or HTLV-II tax protein, and (ii) determining that the donor is a carrier of a disease or a condition related to at least one of HTLV-I or HTLV-II infection. It is unclear whether there another active step is required in the process, because of the limitation "...if the test for at least one of (a), (b) or (c) is positive...".

# Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 8. Claims 11 and 13 are rejected under 35 U.S.C. 102(b) as being anticipated by Zucker-Franklin et al. (The Lancet, vol. 349, p. 999, 1997).

Regarding claims 11 and 13, Zucker-Franklin et al. teach screening of 100 healthy potential blood donors for the presence of HTLV-I Tax DNA by PCR. The donors were also tested for the presence of antibodies to the Tax protein (page 999).

9. No references were found teaching or suggesting claim 12, but it is objected to as being dependent on the rejected claim 11.

Application/Control Number: 09/543,782

Art Unit: 1637

#### Conclusion

10. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Teresa E Strzelecka whose telephone number is (703) 306-5877. The examiner can normally be reached on M-F (8:30-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

September 10, 2002

Hunter Habel